See more : Eagle Bancorp, Inc. (EGBN) Income Statement Analysis – Financial Results
Complete financial analysis of Vertex Pharmaceuticals Incorporated (VRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex Pharmaceuticals Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ASX Limited (ASX.AX) Income Statement Analysis – Financial Results
- Bristol-Myers Squibb Company Ce (CELG-RI) Income Statement Analysis – Financial Results
- Guoan International Limited (0143.HK) Income Statement Analysis – Financial Results
- Deutsche Wohnen SE (DTCWY) Income Statement Analysis – Financial Results
- Furuno Electric Co., Ltd. (6814.T) Income Statement Analysis – Financial Results
Vertex Pharmaceuticals Incorporated (VRTX)
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.87B | 8.93B | 7.57B | 6.21B | 4.16B | 3.05B | 2.49B | 1.70B | 1.03B | 580.42M | 1.21B | 1.53B | 1.41B | 143.37M | 102.05M | 175.50M | 199.01M | 216.36M | 160.89M | 102.72M | 69.14M | 161.09M | 167.49M | 78.13M | 61.60M | 44.40M | 43.80M | 13.30M | 22.10M | 19.60M | 27.90M | 3.80M | 3.20M | 2.30M |
| Cost of Revenue | 1.26B | 1.08B | 904.20M | 736.30M | 547.76M | 409.54M | 275.12M | 210.46M | 125.54M | 60.99M | 130.28M | 279.89M | 80.51M | 12.73M | 14.20M | 15.69M | 13.90M | 12.17M | 10.10M | 5.65M | 3.13M | 28.28M | 39.63M | 4.08M | -3.40M | -4.50M | -3.60M | -3.20M | -3.70M | -3.50M | -3.90M | -2.80M | -1.80M | 0.00 |
| Gross Profit | 8.61B | 7.85B | 6.67B | 5.47B | 3.62B | 2.64B | 2.21B | 1.49B | 906.79M | 519.43M | 1.08B | 1.25B | 1.33B | 130.64M | 87.85M | 159.82M | 185.11M | 204.19M | 150.79M | 97.07M | 66.02M | 132.80M | 127.86M | 74.05M | 65.00M | 48.90M | 47.40M | 16.50M | 25.80M | 23.10M | 31.80M | 6.60M | 5.00M | 2.30M |
| Gross Profit Ratio | 87.21% | 87.90% | 88.06% | 88.14% | 86.84% | 86.56% | 88.95% | 87.64% | 87.84% | 89.49% | 89.25% | 81.67% | 94.29% | 91.12% | 86.08% | 91.06% | 93.01% | 94.38% | 93.72% | 94.50% | 95.48% | 82.44% | 76.34% | 94.78% | 105.52% | 110.14% | 108.22% | 124.06% | 116.74% | 117.86% | 113.98% | 173.68% | 156.25% | 100.00% |
| Research & Development | 3.16B | 2.54B | 3.05B | 1.83B | 1.75B | 1.42B | 1.32B | 1.05B | 996.17M | 855.51M | 918.78M | 806.19M | 707.71M | 637.42M | 550.69M | 516.29M | 513.05M | 371.71M | 248.54M | 192.16M | 199.64M | 203.02M | 148.67M | 84.92M | 72.20M | 58.70M | 51.60M | 35.20M | 41.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.43M | 352.58M | 289.21M | 342.74M | 378.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.40M | 24.50M | 16.20M | 19.60M | 58.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.14B | 944.70M | 840.10M | 770.46M | 658.50M | 557.62M | 496.08M | 432.83M | 377.08M | 305.41M | 362.34M | 436.80M | 400.72M | 187.80M | 129.30M | 101.91M | 84.73M | 57.86M | 43.99M | 42.14M | 39.08M | 49.39M | 47.34M | 27.81M | 26.10M | 18.10M | 11.40M | 7.90M | 7.10M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Other Expenses | 475.50M | -164.80M | 4.90M | 296.42M | 192.18M | -790.00K | -81.38M | 4.13M | -6.71M | 30.40M | -72.67M | 44.99M | 124.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| Operating Expenses | 4.78B | 3.49B | 3.89B | 2.60B | 2.41B | 1.97B | 1.82B | 1.48B | 1.37B | 1.16B | 1.28B | 1.24B | 1.11B | 825.22M | 679.98M | 618.20M | 597.78M | 429.57M | 292.53M | 234.30M | 238.72M | 252.41M | 196.01M | 112.73M | 104.60M | 81.30M | 66.60M | 46.30M | 52.30M | 43.80M | 30.60M | 16.60M | 10.60M | 6.40M |
| Cost & Expenses | 6.04B | 4.57B | 4.80B | 3.34B | 2.96B | 2.38B | 2.10B | 1.69B | 1.50B | 1.22B | 1.41B | 1.52B | 1.19B | 837.95M | 694.18M | 633.89M | 611.69M | 441.74M | 302.63M | 239.95M | 241.84M | 280.69M | 235.64M | 116.81M | 101.20M | 76.80M | 63.00M | 43.10M | 48.60M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Interest Income | 614.70M | 144.60M | 4.90M | 22.24M | 63.68M | 0.00 | 11.75M | 0.00 | 0.00 | 0.00 | 0.00 | 1.94M | 1.88M | 1.96M | 5.01M | 16.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 44.10M | 54.80M | 61.50M | 58.15M | 58.50M | 34.12M | 57.55M | 81.43M | 84.21M | 72.86M | 22.73M | 14.71M | 36.57M | 19.28M | 13.19M | 13.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 181.30M | 148.30M | 125.60M | 109.52M | 106.94M | 72.42M | 61.40M | 61.40M | 62.34M | 63.26M | 48.37M | 38.19M | 35.04M | 30.46M | 30.11M | 32.20M | 27.46M | 25.87M | 27.29M | 29.64M | 23.44M | 25.43M | 17.96M | 9.10M | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| EBITDA | 4.61B | 4.44B | 2.92B | 3.28B | 1.56B | 706.78M | 103.26M | 75.46M | -411.25M | -598.76M | -554.75M | 42.46M | 133.94M | -704.89M | -598.88M | -426.19M | -385.21M | -199.52M | -114.45M | -107.59M | -264.53M | -123.05M | -97.14M | -24.65M | -44.30M | -43.20M | -15.60M | -36.30M | -22.80M | -17.20M | 5.10M | -7.20M | -3.80M | -4.10M |
| EBITDA Ratio | 46.66% | 48.65% | 36.82% | 51.37% | 35.02% | 21.76% | 12.51% | 0.90% | -45.83% | -105.28% | 41.63% | 0.27% | 15.72% | -461.86% | -531.80% | -260.35% | -189.99% | -93.32% | -56.52% | -101.15% | -96.10% | -58.43% | -14.39% | -18.77% | -52.92% | -62.84% | -35.62% | -127.07% | -128.05% | -106.12% | 13.26% | -242.11% | -143.75% | -178.26% |
| Operating Income | 4.31B | 4.31B | 2.78B | 2.86B | 1.20B | 635.15M | 123.24M | 9.94M | -468.66M | -692.41M | -903.45M | 2.33M | 113.82M | -696.08M | -613.41M | -462.71M | -419.79M | -229.04M | -149.87M | -154.81M | -264.53M | -119.60M | -91.80M | -38.68M | -39.60M | -32.40M | -19.20M | -29.80M | -26.50M | -20.70M | 1.20M | -10.00M | -5.60M | -4.10M |
| Operating Income Ratio | 43.65% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | -45.40% | -119.30% | -74.54% | 0.15% | 8.07% | -485.51% | -601.10% | -263.65% | -210.94% | -105.86% | -93.15% | -150.71% | -382.59% | -74.25% | -54.81% | -49.51% | -64.29% | -72.97% | -43.84% | -224.06% | -119.91% | -105.61% | 4.30% | -263.16% | -175.00% | -178.26% |
| Total Other Income/Expenses | 72.30M | -75.00M | -51.70M | 62.80M | 197.42M | -34.91M | -138.93M | -77.30M | -90.92M | -42.46M | -366.11M | -59.11M | -53.38M | -58.55M | -28.17M | 2.86M | 28.51M | 21.10M | -53.55M | -11.44M | 67.76M | 28.30M | -2.79M | -16.16M | 10.30M | 0.00 | 0.00 | 0.00 | 5.50M | 3.60M | 900.00K | 2.00M | 800.00K | 4.10M |
| Income Before Tax | 4.38B | 4.23B | 2.73B | 3.12B | 1.39B | 600.24M | -15.69M | -67.37M | -559.58M | -734.88M | -976.12M | -12.38M | 60.45M | -754.63M | -642.18M | -464.18M | -426.91M | -206.89M | -173.39M | -158.51M | -347.35M | -119.66M | -117.89M | -53.61M | -40.30M | 0.00 | 0.00 | -39.50M | -21.00M | -17.10M | 2.10M | -8.00M | -4.80M | 0.00 |
| Income Before Tax Ratio | 44.38% | 47.39% | 36.05% | 50.22% | 33.51% | 19.70% | -0.63% | -3.96% | -54.21% | -126.61% | -80.54% | -0.81% | 4.28% | -526.35% | -629.28% | -264.48% | -214.52% | -95.63% | -107.77% | -154.31% | -502.38% | -74.28% | -70.39% | -68.62% | -65.42% | 0.00% | 0.00% | -296.99% | -95.02% | -87.24% | 7.53% | -210.53% | -150.00% | 0.00% |
| Income Tax Expense | 760.20M | 910.40M | 388.30M | 405.15M | 218.11M | -1.49B | -107.32M | 16.67M | 30.38M | 6.96M | -288.57M | 38.75M | 19.27M | 19.28M | 19.34M | -30.73M | -21.39M | -18.50M | 61.68M | 29.01M | 24.06M | -10.98M | -1.92M | 976.00K | 1.40M | 700.00K | 600.00K | 10.20M | -5.00M | -3.10M | 100.00K | -1.50M | -500.00K | 4.30M |
| Net Income | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.10B | 263.48M | -112.05M | -558.12M | -738.56M | -445.03M | -107.03M | 29.57M | -754.63M | -641.58M | -459.85M | -391.28M | -206.89M | -203.42M | -166.25M | -196.77M | -108.62M | -66.23M | -39.66M | -41.00M | -33.10M | -19.80M | -40.00M | -21.50M | -17.60M | 2.00M | -8.50M | -5.10M | -4.30M |
| Net Income Ratio | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% | 10.59% | -6.58% | -54.06% | -127.25% | -36.72% | -7.01% | 2.10% | -526.35% | -628.70% | -262.02% | -196.61% | -95.63% | -126.43% | -161.85% | -284.59% | -67.43% | -39.54% | -50.76% | -66.56% | -74.55% | -45.21% | -300.75% | -97.29% | -89.80% | 7.17% | -223.68% | -159.38% | -186.96% |
| EPS | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.25 | 1.06 | -0.46 | -2.32 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| EPS Diluted | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| Weighted Avg Shares Out | 257.70M | 256.10M | 257.70M | 259.84M | 256.73M | 254.29M | 248.86M | 243.59M | 240.84M | 234.92M | 224.83M | 211.95M | 204.89M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
| Weighted Avg Shares Out (Dil) | 260.50M | 259.10M | 259.90M | 263.40M | 260.67M | 259.19M | 253.23M | 244.69M | 241.31M | 235.31M | 224.91M | 211.95M | 208.81M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $460, moving -1.06% from the previous trading session.
The Best Biotech Stock to Invest $1,000 in Right Now
Vertex Pharmaceuticals is unusually resilient for a biotech stock. The company has spectacular growth prospects with multiple promising late-stage programs.
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Diversification can help improve your portfolio's prospects in both bull and bear markets. Vertex is a top healthcare stock with an impressive track record and a superior outlook.
Biotech stock plays outside of GLP-1 weight-loss market
BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 weight-loss space. The sky-high demand for GLP-1 weight-loss drugs has led the biotech sector to reach...
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Moderna hopes to win approvals for 10 programs by 2027. Vertex Pharmaceuticals could have multiple new blockbuster drugs on the market over the next few years.
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us...
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than placebos and potentially more powerful than NSAIDs and ibuprofen in post-surgery...
3 Stocks to Buy and Hold Forever
AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.
Source: https://incomestatements.info
Category: Stock Reports